SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024 16:30 ET
|
Scynexis
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
April 30, 2024 16:05 ET
|
Scynexis
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 09, 2024 16:05 ET
|
Scynexis
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
March 28, 2024 16:01 ET
|
Scynexis
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study...
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
January 30, 2024 16:05 ET
|
Scynexis
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
January 29, 2024 17:15 ET
|
Scynexis
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosisCombination of SCY-247 and...
DEADLINE ALERT for SCYX, LICY, and FMC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
January 08, 2024 11:15 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
January 08, 2024 07:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been...
SCYX DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action – SCYX
January 06, 2024 15:21 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and...
SCYNEXIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc. and Encourages Investors to Contact the Firm
January 05, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against...